Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Average Rating of “Hold” from Brokerages

Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) have received an average rating of “Hold” from the five research firms that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $7.30.

A number of equities analysts recently weighed in on ESPR shares. Cantor Fitzgerald assumed coverage on shares of Esperion Therapeutics in a research report on Tuesday, December 17th. They set an “overweight” rating and a $8.00 target price for the company. StockNews.com downgraded shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 15th. HC Wainwright reaffirmed a “buy” rating on shares of Esperion Therapeutics in a report on Friday. The Goldman Sachs Group began coverage on Esperion Therapeutics in a research note on Wednesday, December 18th. They set a “neutral” rating and a $4.00 price target for the company. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $6.00 price objective on shares of Esperion Therapeutics in a research note on Friday, December 13th.

Esperion Therapeutics Trading Up 7.8 %

NASDAQ ESPR opened at $2.34 on Friday. Esperion Therapeutics has a 12 month low of $1.58 and a 12 month high of $3.94. The stock’s 50 day moving average is $2.46 and its 200 day moving average is $2.18. The stock has a market cap of $461.07 million, a PE ratio of -3.66 and a beta of 1.01.

Institutional Investors Weigh In On Esperion Therapeutics

Institutional investors have recently modified their holdings of the stock. BOKF NA purchased a new stake in Esperion Therapeutics during the 2nd quarter valued at $26,000. Traphagen Investment Advisors LLC purchased a new stake in shares of Esperion Therapeutics in the third quarter valued at $27,000. Xponance Inc. bought a new stake in shares of Esperion Therapeutics in the 2nd quarter worth about $28,000. National Bank of Canada FI lifted its holdings in shares of Esperion Therapeutics by 115.9% in the 2nd quarter. National Bank of Canada FI now owns 19,050 shares of the biopharmaceutical company’s stock worth $44,000 after acquiring an additional 10,225 shares during the last quarter. Finally, Versor Investments LP purchased a new position in shares of Esperion Therapeutics during the 3rd quarter worth about $44,000. 47.39% of the stock is owned by institutional investors.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.